Jalkanen K.
- Country
- Finland
- Department
- Comprehensive Cancer Center
Research Overview
- Long-term Efficacy and Safety of Belzutifan and Lenvatinib in Patients with von Hippel-Lindau Disease-Associated Tumors and Other Advanced Solid Tumors
- Early Access Study of Zongertinib for the Treatment of Cancer in Patients Eligible for Anticancer Therapy
- Phase 1/2 Study of ODM-212 Plus Anti-Cancer Therapy in Patients With Advanced Solid Tumours: Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy
Data & Insights
Has run more than one trial at 158 of 374 partner sites.
Specializations
Renal Cell Carcinoma Expertise
This investigator demonstrates significant involvement in treating advanced renal cell carcinoma, with particular focus on both clear cell RCC and metastatic RCC. Their research encompasses various therapeutic approaches including targeted therapies and immunotherapy combinations.
- First-line RCC treatments
- Advanced disease management
- Adjuvant therapy approaches
Solid Tumor Research
The investigator has extensive experience in treating various advanced solid tumors, including specialized work with KRAS G12C-mutant cancers and biliary tract cancer. Their research includes novel therapeutic combinations and targeted approaches.
- NSCLC treatment strategies
- Colorectal cancer therapies
- HER2-positive cancers
Innovative Treatment Approaches
The investigator works with cutting-edge therapeutic modalities including immunotherapy combinations and targeted molecular therapies. Their research incorporates novel treatment strategies for various oncological conditions.
- Combination immunotherapy
- Molecular targeted agents
- First-in-human studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.